Since the America Invents Act became effective in 2012, use of contested proceedings in the US Patent & Trademark Office have grown significantly and now are involved with almost every significant patent litigation in the US. These include the frequently used Inter Partes Review (IPR) process as well as the increasingly available Post Grant Review (PGR) process. Understanding the impact of IPR and PGR institutions and final written decisions on your life science patent portfolio and product protection or as a challenger looking to develop competing life science products is a critical aspect of intellectual property law as well as directly impacting pharmaceutical business and market development.
With a significant number of petitions and decisions now available in the life sciences space, attorney Ha Kung Wong will parse out trends and other important information that can help you effectively prepare for or respond to a petition, such as strategically taking advantage of which claims to challenge and how to prepare claims for challenge. Additionally, for those interested in biologics, he will touch on the new FDA Interchangeable Guidance and how it might impact your patent strategy in contested proceedings.
Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Ha Kung has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives, psychotropic agents, siRNA and other pharmaceuticals. Mr. Wong also has extensive experience with inter partes review (IPR), post grant review (PGR), intellectual property counseling, pre-suit investigations, licensing and due diligence.
Mr. Wong is the recipient of the 2017 ILO Client Choice Individual Award for Intellectual Property in New York, was named to The National Law Journal’s 2017 inaugural list of Elite Boutique Trailblazers and was recognized as a 2018 LMG Life Sciences Star. He serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a Furthered 40 by Lawline for his contributions. He is also an Advisory Board Member for The Center for Biosimilars.